Fennec Pharmaceuticals Appoints Jeffrey S. Hackman as Chief Executive Officer and Director
Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX) has appointed Jeffrey S. Hackman as its new Chief Executive Officer and Board member, effective August 16, 2024. Hackman brings over 30 years of commercial leadership experience, including 12 years in oncology across various companies. He has overseen more than 10 product launches and successfully commercialized products relevant to PEDMARK® markets.
PEDMARK® is the first and only approved treatment to reduce the risk of cisplatin-induced ototoxicity in pediatric cancer patients. Hackman's appointment aims to expand PEDMARK®'s use in community oncology and the adolescent and young adult (AYA) population. Rosty Raykov, the current CEO since 2009, will remain on the Board of Directors.
Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX) ha nominato Jeffrey S. Hackman come nuovo Amministratore Delegato e membro del Consiglio di Amministrazione, con effetto dal 16 agosto 2024. Hackman porta con sé oltre 30 anni di esperienza nella leadership commerciale, tra cui 12 anni nel settore oncologico presso varie aziende. Ha supervisionato oltre 10 lanci di prodotto e ha commercializzato con successo prodotti rilevanti per i mercati di PEDMARK®.
PEDMARK® è il primo e unico trattamento approvato per ridurre il rischio di ototossicità indotta da cisplatino nei pazienti pediatrici affetti da cancro. La nomina di Hackman mira ad espandere l'uso di PEDMARK® nella oncologia comunitaria e nella popolazione adolescenti e giovani adulti (AYA). Rosty Raykov, attuale CEO dal 2009, rimarrà nel Consiglio di Amministrazione.
Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX) ha designado a Jeffrey S. Hackman como su nuevo Director Ejecutivo y miembro de la Junta, con efecto a partir del 16 de agosto de 2024. Hackman aporta más de 30 años de experiencia en liderazgo comercial, incluyendo 12 años en oncología en diversas empresas. Ha supervisado más de 10 lanzamientos de producto y ha comercializado con éxito productos relevantes en los mercados de PEDMARK®.
PEDMARK® es el primer y único tratamiento aprobado para reducir el riesgo de ototoxicidad inducida por cisplatino en pacientes pediátricos con cáncer. La designación de Hackman tiene como objetivo expandir el uso de PEDMARK® en la oncología comunitaria y en la población de adolescentes y adultos jóvenes (AYA). Rosty Raykov, actual CEO desde 2009, permanecerá en la Junta Directiva.
Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX)가 제프리 S. 해크먼을 새로운 CEO이자 이사회 멤버로 임명했다, 이는 2024년 8월 16일부터 효력이 발생한다. 해크먼은 30년 이상의 상업 리더십 경험을 보유하고 있으며, 이 중 12년은 다양한 회사에서 종양학 분야에서 근무했다. 그는 10개 이상의 제품 출시를 감독하였으며, PEDMARK® 시장과 관련된 제품을 성공적으로 상용화하였다.
PEDMARK®는 소아 암 환자에게서 시스플라틴으로 인한 이독성을 줄이기 위해 승인된 첫 번째이자 유일한 치료제이다. 해크먼의 임명은 PEDMARK®의 사용을 커뮤니티 종양학 및 청소년과 젊은 성인(AYA) 집단으로 확장하는 것을 목표로 하고 있다. 2009년부터 CEO로 재직 중인 로스티 레이코프는 이사회를 계속 유지하게 된다.
Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX) a nommé Jeffrey S. Hackman en tant que nouveau Directeur Général et membre du Conseil d'Administration, avec effet au 16 août 2024. Hackman apporte plus de 30 ans d'expérience en leadership commercial, dont 12 ans dans le domaine de l'oncologie au sein de diverses entreprises. Il a supervisé plus de 10 lancements de produits et a commercialisé avec succès des produits pertinents pour les marchés de PEDMARK®.
PEDMARK® est la première et unique traitement approuvé pour réduire le risque d'ototoxicité induite par le cisplatine chez les patients pédiatriques atteints de cancer. La nomination de Hackman vise à étendre l'utilisation de PEDMARK® en oncologie communautaire et auprès de la population des adolescents et jeunes adultes (AYA). Rosty Raykov, actuel PDG depuis 2009, restera au Conseil d'Administration.
Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX) hat Jeffrey S. Hackman zum neuen Geschäftsführer und Mitglied des Vorstands ernannt, wirksam zum 16. August 2024. Hackman bringt über 30 Jahre Erfahrung in der kommerziellen Führung mit, darunter 12 Jahre in der Onkologie in verschiedenen Unternehmen. Er hat über 10 Produkteinführungen beaufsichtigt und Produkte, die für die Märkte von PEDMARK® relevant sind, erfolgreich kommerzialisiert.
PEDMARK® ist die erste und einzige genehmigte Behandlung zur Reduzierung des Risikos einer durch Cisplatin verursachten Ototoxizität bei krebskranken Kindern. Hacksmans Ernennung soll die Verwendung von PEDMARK® in der Gemeinschaftsonkologie und in der Altersgruppe von Jugendlichen und jungen Erwachsenen (AYA) erweitern. Rosty Raykov, der seit 2009 als CEO tätig ist, wird im Vorstand verbleiben.
- Appointment of experienced CEO with 30+ years of commercial leadership
- New CEO has expertise in oncology product commercialization
- Potential for expanded use of PEDMARK® in community oncology and AYA population
- PEDMARK® is the first and only approved treatment for cisplatin-induced ototoxicity in pediatric cancer patients
- Change in leadership may cause temporary disruption in company operations
~ Accomplished Industry Leader Brings Extensive Commercialization and Oncology Expertise ~
~ Assumes Leadership Role at Critical Time to Expand Use of PEDMARK®, the First and Only Approved Treatment to Reduce the Risk of Cisplatin-Induced Ototoxicity ~
RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced the appointment of Mr. Jeff Hackman as its Chief Executive Officer (CEO) and a member of the Board of Directors, effective on or about August 16, 2024. Jeff will guide Fennec’s strategic direction for operational success in the expansion of PEDMARK® use in community oncology and the adolescent and young adult (AYA) population.
“Jeff’s appointment comes at a pivotal time for Fennec as we continue to advance PEDMARK®, the first and only therapy approved in the U.S. and Europe to reduce the risk of permanent damage from cisplatin-induced ototoxicity in pediatric cancer patients,” said Dr. Khalid Islam, Chairman of Fennec Pharmaceuticals. “We are confident that Jeff’s deep expertise in the commercialization of new therapies across multiple oncology indications, and extensive experience leading organizational growth and transformation, will bring tremendous value to Fennec.”
Jeff brings to Fennec more than 30 years of commercial leadership experience, including oversight of more than 10 product launches across a wide range of therapeutic areas and markets. His tenure in oncology spans the last 12 years across Sigma Tau, Baxalta, Shire, and EUSA Pharma, where he was responsible for the U.S. commercial organizations and managing the company’s product portfolio in multiple franchises, which generated billions in revenues over the years. More specifically, Jeff has successfully commercialized products that are specifically relevant to the PEDMARK® markets, including the outpatient oncology community and the AYA population.
“I am excited to lead Fennec and look forward to working with management and the Board of Directors to bring this much-needed treatment to oncology patients,” said Jeffrey S. Hackman, incoming chief executive officer of Fennec Pharmaceuticals.
Rosty Raykov, who has served as Fennec’s CEO since 2009, will remain a member of the Board of Directors. “Rosty’s unwavering commitment and leadership since 2009 has been critical to Fennec in bringing a much-needed therapy to the oncology population at risk of irreversible hearing loss, which can have a profound lifelong impact on patients,” said Khalid Islam.
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of PEDMARK® and Pedmarqsi® to reduce the risk of cisplatin-induced ototoxicity in pediatric patients. Further, PEDMARK received FDA approval in September 2022, and Pedmarqsi received European Commission Marketing Authorization in June 2023 and U.K. approval in October 2023. PEDMARK has received Orphan Drug Exclusivity in the U.S. for seven years of market protection and Pedmarqsi has received Pediatric Use Marketing Authorization in Europe, which includes eight years plus two years of data and market protection. Fennec has a license agreement with Oregon Health and Science University (OHSU) for exclusive worldwide license rights to intellectual property directed to sodium thiosulfate and its use for chemoprotection, including the reduction of risk of ototoxicity induced by platinum chemotherapy, in humans. For more information, please visit www.fennecpharma.com.
For further information, please contact:
Investors:
Robert Andrade
Chief Financial Officer
Fennec Pharmaceuticals Inc.
+1 919-246-5299
Corporate and Media:
Lindsay Rocco
Elixir Health Public Relations
+1 862-596-1304
lrocco@elixirhealthpr.com
FAQ
Who is the new CEO of Fennec Pharmaceuticals (FENC)?
What is PEDMARK®, the product developed by Fennec Pharmaceuticals (FENC)?
What experience does the new CEO bring to Fennec Pharmaceuticals (FENC)?
When will Jeffrey S. Hackman start as CEO of Fennec Pharmaceuticals (FENC)?
